دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Dermatology is finally talking about race
J. Guckian,J.R. Ingram,N. Rajan,E. Linos
doi : 10.1111/bjd.20599
Volume 185, Issue 5 p. 875-876
Commentary on the British Association of Dermatologists UK basal cell carcinoma guidelines 2021: all together now …
M. D. Moncrieff,J. P. Nobes
doi : 10.1111/bjd.20694
Volume 185, Issue 5 p. 877-877
Basal cell carcinoma (BCC) is an extremely common diagnosis in the UK.1 Indeed, it is so common that the true national incidence is difficult to quantify accurately.2 Regardless, it is clear that BCC represents a significant burden on healthcare resources across all sectors of the National Health Service (NHS), from primary care to tertiary referral cancer centres. This burden has more than doubled since the 1990s and, as the UK’s predominantly white population ages yet further, the trend shows no signs of abating.1 Given the diversity of tumour presentation, the plurality of the agencies treating the disease and the sundry treatment options available to effect a cure, it is crucial to have a standardization of care for BCC to ensure effective and efficient use of the overburdened resources of the NHS.
Hidradenitis suppurativa: redirecting a life trajectory
J. Hsiao,V. Shi
doi : 10.1111/bjd.20696
Volume 185, Issue 5 p. 878-878
Hidradenitis suppurativa (HS) imposes a tremendous disease burden on the lives of patients who are affected. The last decade has witnessed an increase in HS publications1 and a burgeoning therapeutic pipeline, but perhaps one of the most important advances has been the highlighting of the patient experience and emphasis on important gaps that need to be addressed. One benefit of open-ended qualitative studies includes the ability to discover new important themes without investigator-imposed restrictions to patient responses. In addition, the power of direct quotations from patients, providing first-hand descriptions of the patients’ experiences, cannot be overstated.
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis
P. C. M. van de Kerkhof
doi : 10.1111/bjd.20624
Volume 185, Issue 5 p. 879-879
In general, patients with severe psoriasis require a systemic treatment as maintenance for many years. Therefore, the long-term efficacy and cumulative toxicity of antipsoriatic treatments over long time periods have to be reconciled. Patients with severe psoriasis may have been treated in the past with photo(chemo)therapy. Furthermore, patients with psoriasis have an increased risk of cancer and cancer-related mortality involving a range of site-specific cancers, according to a study by the Global Psoriasis Atlas.1 Whether specific lifestyle factors, antipsoriatic treatments or the inflammatory processes in psoriasis are responsible for the increased cancer risk in patients with psoriasis has to be investigated. Immunosuppressive treatments, including anti-interleukin (IL)-17 treatments, may facilitate the development of malignancies by decreased immunosurveillance. Long-term (? 12?months) treatment of psoriasis with a tumour necrosis factor-? inhibitor has been reported to be associated with increased risk for malignancy.2 What is the cancer risk for the anti-IL-17 molecule secukinumab?
Medico-administrative databases as research tools for joint European epidemiological studies
C. Droitcourt
doi : 10.1111/bjd.20637
Volume 185, Issue 5 p. 879-880
In this issue of the BJD, Löfvendahl et?al. report estimates of the prevalence and incidence of palmoplantar pustulosis (PPP), and the prevalence of psoriasis vulgaris among patients with PPP recorded in the National Swedish Patient Register.1 This is the largest recent study on the prevalence and incidence of PPP at a national level.
New technology use needs patient input
R. M. Hewitt,C. Bundy
doi : 10.1111/bjd.20634
Volume 185, Issue 5 p. 880-881
Recent rapid technological developments have transformed the organization and delivery of healthcare services.1 Arguably, dermatology has led the way in this, and teledermatology methods, including asynchronous store and forward (SAF) and synchronous video teleconferencing (VTC), are now widely embedded within dermatology service provision to facilitate remote patient care.2 The SARS-CoV-2 pandemic has accelerated the use of digital health technologies, particularly remote consultations via telephone and video, which have allowed some continuity of patient care during such unprecedented times.1 These changes are occurring against a backdrop of National Health Service policies such as ‘no decision about me without me’, which advocate a patient-centred approach.3 However, with little to no data to show whether the shift towards remote healthcare is endorsed by patients, the extent to which modern service delivery methods benefit service users vs. service providers remains unclear.
Another step on the road towards standardized outcome reporting for congenital melanocytic naevi: one more to go!
M.V. Heppt,T. Steeb,C. Berking
doi : 10.1111/bjd.20691
Volume 185, Issue 5 p. 881-882
A core outcome set (COS) comprises a standardized consented minimum set of domain and outcome measurement instruments to facilitate uniform reporting in patient care and research. A COS is usually developed in a stepwise process starting from a set of domains to outcomes and, ultimately, to specific measurement instruments.1 While the first two items relate to what should be measured, the latter one defines how a condition of interest should be assessed.
Stratified psoriasis treatment plans: why is patient preference information needed?
J.M. Gonzalez,S.D. Reed,F.R. Johnson
doi : 10.1111/bjd.20697
Volume 185, Issue 5 p. 882-883
Patients with psoriasis today have more options to treat their disease than ever before. The proliferation of new treatments obviously is a positive development; however, the availability of numerous options poses challenges in clinical decision making. Selecting treatments for specific individuals is particularly difficult in light of uncertainties related to efficacy and serious adverse events. The article by Dalal et?al. published in this issue of the BJD, ‘Patient preferences for stratified medicine in psoriasis: a discrete choice experiment’,1 discusses how having a variety of treatment options offers opportunities to improve overall patient wellbeing. The article highlights the essential role of patient preference information in achieving this objective.
Identification of novel skin ageing genes: evidence from across the pigmentary continuum
A. K. Langton,R. E. B. Watson
doi : 10.1111/bjd.20636
Volume 185, Issue 5 p. 883-884
Skin pigmentation is likely the most striking phenotypic differences among humans, expressed as a continuum of skin colour, with the vast majority of the world’s population having ‘ethnic skin’1 or skin of colour. Skin pigmentation plays a key role in determining its susceptibility to external insults, primarily exposure to ultraviolet radiation (UVR).2 However, it further influences the prevalence of dermatological disease, such as the incidence of keloid scars3 or keratinocyte carcinoma.4 Despite differences in susceptibility to the development of skin disease, studies of human skin – its anatomy, physiology or pathobiology – often focus on lightly pigmented, white individuals of European heritage. Within dermatology, an appreciation of understanding skin – in all of its diversity – is now beginning to emerge.
Mycosis fungoides-derived exosomes and their microRNA-1246 cargo: a message from the skin
I. Pospischil,E. Guenova
doi : 10.1111/bjd.20695
Volume 185, Issue 5 p. 884-886
Exosomes are small extracellular vesicles containing proteins, lipids and nucleic acids that facilitate cell–cell communication, influence local and distant microenvironments, and have implications in cancer pathogenesis. MicroRNAs (miRNAs), which act as key post-transcriptional regulators of gene expression, are an important part of the exosome content.1, 2 In recent years, evidence has accumulated that dysregulated miRNA expression interferes with tumour immunity and plays a crucial role in the pathogenesis of diverse malignancies including cutaneous T-cell lymphoma (CTCL).2, 3 While data addressing the role of exosomes in the most common CTCL, mycosis fungoides (MF), are only just increasing, some miRNAs have already caught attention as promising candidates for much needed diagnostic and prognostic biomarkers and novel therapeutic targets.4-6
The promise and challenges of cell therapy for psoriasis*
S.M. Lwin,J.A. Snowden,C.E.M. Griffiths
doi : 10.1111/bjd.20517
Volume 185, Issue 5 p. 887-898
British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021*
I. Nasr,E.J. McGrath,C.A. Harwood,J. Botting,P. Buckley,P.G. Budny,P. Fairbrother,K. Fife,G. Gupta,M. Hashme,S. Hoey,J.T. Lear,R. Mallipeddi,E. Mallon,R.J. Motley,C. Newlands,J. Newman,E.V. Pynn,N. Shroff,D.N. Slater,L.S. Exton,M.F. Mohd Mustapa,M.C. Ezejimofor,on behalf of the British Association of Dermatologists’ Clinical Standards Unit
doi : 10.1111/bjd.20524
Volume 185, Issue 5 p. 899-920
This is an updated guideline prepared for the British Association of Dermatologists (BAD) Clinical Standards Unit, which includes the Therapy & Guidelines (T&G) subcommittee. Members of the Clinical Standards Unit who have been involved are N.J. Levell (Chairman T&G), B. McDonald (Assistant Honorary Secretary), F.S. Worsnop, P. Rakvit, S.L. Chua, P. Laws, A. Bardhan, L.S. Exton (BAD Guideline Research Fellow), M. Hashme (BAD Information Scientist), M.C. Ezejimofor (BAD Guideline Research Fellow) and M.F. Mohd Mustapa (BAD Clinical Standards Manager).
Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review*
L. Howells,N. Lancaster,M. McPhee,C. Bundy,J.R. Ingram,P. Leighton,K. Henaghan-Sykes,K.S. Thomas
doi : 10.1111/bjd.20523
Volume 185, Issue 5 p. 921-934
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up
M. Lebwohl,A. Deodhar,C.E.M. Griffiths,M.A. Menter,D. Poddubnyy,W. Bao,V. Jehl,K. Marfo,P. Primatesta,A. Shete,V. Trivedi,P.J. Mease
doi : 10.1111/bjd.20136
Volume 185, Issue 5 p. 935-944
Prevalence and incidence of palmoplantar pustulosis in Sweden: a population-based register study*
S. Löfvendahl,J. M. Norlin,M. Schmitt-Egenolf
doi : 10.1111/bjd.20087
Volume 185, Issue 5 p. 945-951
Alcohol misuse is associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study*
I.Y.K. Iskandar,M. Lunt,R.J. Thorneloe,L. Cordingley,C.E.M. Griffiths,D.M. Ashcroft,on behalf the British Association of Dermatologists Biologics and Immunomodulators Register and Psoriasis Stratification to Optimise Relevant Therapy Study Groups
doi : 10.1111/bjd.20577
Volume 185, Issue 5 p. 952-960
Views on mobile health apps for skin cancer screening in the general population: an in-depth qualitative exploration of perceived barriers and facilitators*
T.E. Sangers,M. Wakkee,E.C. Kramer-Noels,T. Nijsten,M. Lugtenberg
doi : 10.1111/bjd.20441
Volume 185, Issue 5 p. 961-969
Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research (the OCOMEN project): part 2*
A.C. Fledderus,S.G.M.A. Pasmans,A. Wolkerstorfer,W. Oei,H.C. Etchevers,M.S. van Kessel,C.M.A.M. van der Horst,P.I. Spuls
doi : 10.1111/bjd.20437
Volume 185, Issue 5 p. 970-977
Congenital melanocytic naevi (CMN) can have a great impact on patients’ lives owing to perceived stigmatization, and the risk of melanoma development and neurological complications. Development of a core outcome set (COS) for care and research in CMN will allow standard reporting of outcomes. This will enable comparison of outcomes, allowing professionals to offer advice about the best management options. In previous research, stakeholders (patients, parents and professionals) reached consensus on the core domains of the COS. To select the appropriate measurement instruments, the domains should be specified by outcomes.
Patient preferences for stratified medicine in psoriasis: a discrete choice experiment*
G. Dalal,S.J. Wright,C.M. Vass,N.J. Davison,G. Vander Stichele,C.H. Smith,C.E.M. Griffiths,K. Payne, on behalf of the PSORT consortium
doi : 10.1111/bjd.20482
Volume 185, Issue 5 p. 978-987
A genome-wide association study identifies novel gene associations with facial skin wrinkling and mole count in Latin Americans
Y. Chen,M. André,K. Adhikari,M. Blin,B. Bonfante,J. Mendoza-Revilla,M. Fuentes-Guajardo,S. Palmal,J.C. Chacón-Duque,M. Hurtado,V. Villegas,V. Granja,C. Jaramillo,W. Arias,R.B. Lozano,P. Everardo-Martínez,J. Gómez-Valdés,H. Villamil-Ramírez,C.C.S. de Cerqueira,T. Hünemeier,V. Ramallo,R. Gonzalez-José,L. Schüler-Faccini,M.-C. Bortolini,V. Acuña-Alonzo,S. Canizales-Quinteros,C. Gallo,G. Poletti,G. Bedoya,F. Rothhammer,D. Balding,D.J. Tobin,S. Wang,P. Faux,A. Ruiz-Linares
doi : 10.1111/bjd.20436
Volume 185, Issue 5 p. 988-998
Mycosis fungoides-derived exosomes promote cell motility and are enriched with microRNA-155 and microRNA-1246, and their plasma-cell-free expression may serve as a potential biomarker for disease burden
L. Moyal,C. Arkin,B. Gorovitz-Haris,C. Querfeld,S. Rosen,J. Knaneh,I. Amitay-Laish,H. Prag-Naveh,J. Jacob-Hirsch,E. Hodak
doi : 10.1111/bjd.20519
Volume 185, Issue 5 p. 999-1012
Single-cell RNA sequencing profiling in a patient with discordant primary cutaneous B-cell and T-cell lymphoma reveals micromilieu-driven immune skewing
C. Jonak,N. Alkon,K. Rindler,T.B. Rojahn,L.E. Shaw,S. Porkert,W. Weninger,F. Trautinger,G. Stingl,P. Tschandl,L. Cerroni,M. Farlik,P.M. Brunner
doi : 10.1111/bjd.20512
Volume 185, Issue 5 p. 1013-1025
Air pollution-induced tanning of human skin*
S. Grether-Beck,I. Felsner,H. Brenden,A. Marini,T. Jaenicke,N. Aue,T. Welss,I. Uthe,J. Krutmann
doi : 10.1111/bjd.20483
Volume 185, Issue 5 p. 1026-1034
Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity*
E. Papadavid,E. Kapniari,V. Pappa,V. Nikolaou,T. Iliakis,M. Dalamaga,C. Jonak,S. Porkert,S. Engelina,P. Quaglino,P.L. Ortiz-Romero,C. Vico,A. Cozzio,F. Dimitriou,R. Guiron,E. Guenova,E. Hodak,M. Bagot,J. Scarisbrick
doi : 10.1111/bjd.20588
Volume 185, Issue 5 p. 1035-1044
Sebaceous tumours: a prototypical class of skin tumour for universal germline genetic testing
R. Gallon,N. Kibbi,S. Cook,M. Santibanez-Koref,M.S. Jackson,J. Burn,N. Rajan
doi : 10.1111/bjd.20522
Volume 185, Issue 5 p. 1045-1046
Challenging the association of hepatitis C and pyoderma gangrenosum
D. Croitoru,C. Sibbald,A. Alavi,S. Brooks,V. Piguet
doi : 10.1111/bjd.20566
Volume 185, Issue 5 p. 1047-1048
COVID-19 outcomes in patients with autoimmune blistering disease
E. Hwang,M.M. Tomayko
doi : 10.1111/bjd.20571
Volume 185, Issue 5 p. 1048-1050
Patient-reported skin reactions to 5% 5-fluorouracil in treatment of actinic keratosis
S. Ahmady,E.M.M. Oyen,M.H.E. Jansen,P.J. Nelemans,J.P.H.M. Kessels,N.W.J. Kelleners-Smeets,K. Mosterd
doi : 10.1111/bjd.20570
Volume 185, Issue 5 p. 1050-1052
Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort
M. Beylot-Barry,J. Seneschal,D. Tran,H. Bachelez,N. Beneton,A. Dupuy,P. Joly,D. Jullien,E. Mahé,C. Paul,M.-A. Richard,E. Sbidian,M. Viguier,O. Chosidow,F. Tubach
doi : 10.1111/bjd.20585
Volume 185, Issue 5 p. 1052-1054
Global data analysis supports smoking as the fundamental element associated with geographical sex disparities in hidradenitis suppurativa
C.-B. Chu,C.-C. Yang,S.-J. Tsai
doi : 10.1111/bjd.20581
Volume 185, Issue 5 p. 1054-1056
Cemiplimab-rwlc in advanced cutaneous squamous cell carcinoma: real-world experience in a French dermatology department
T. Guillaume,E. Puzenat,D. Popescu,F. Aubin,C. Nardin
doi : 10.1111/bjd.20569
Volume 185, Issue 5 p. 1056-1058
Male patients with rosacea have increased risk for migraine: a population-based study
S-P. Sinikumpu,H. Vähänikkilä,J. Jokelainen,K. Tasanen,L. Huilaja
doi : 10.1111/bjd.20578
Volume 185, Issue 5 p. 1058-1061
Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous T-cell lymphoma: nine cases
C. Skayem,M. Beylot-Barry,A. de Masson,O. Dereure,C. Ram-Wolff,M. Bagot,B. Vergier,M. Battistella,N. Ortonne,S. Ingen-Housz-Oro
doi : 10.1111/bjd.20580
Volume 185, Issue 5 p. 1061-1063
Is urinary incontinence associated with vulval lichen sclerosus in women? A cross-sectional study
L. Kirby,S. Gran,F. Orekoya,C. Owen,R. Simpson
doi : 10.1111/bjd.20583
Volume 185, Issue 5 p. 1063-1065
The additional diagnostic value of optical coherence tomography in clinically diagnosed basal cell carcinomas undergoing direct surgical excision
F. Adan,P.J. Nelemans,N.W.J. Kelleners-Smeets,J.P.H.M. Kessels,T. Brinkhuizen,K. Mosterd
doi : 10.1111/bjd.20579
Volume 185, Issue 5 p. 1065-1066
The BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) glossary: developing a lingua franca to facilitate data harmonization and cross-cohort analyses
C. Broderick,N. Christian,C. Apfelbacher,A.L. Bosma,N. Dand,S. Ghosh,N. Hangel,M. Hübenthal,M.A. Middelkamp-Hup,J.L. Min,A.H. Musters,L. Paternoster,E. Rodríguez,V. Satagopam,P. Scordis,P.I. Spuls,S. Szymczak,S. Weidinger,C.H. Smith,C. Flohr, on behalf of the BIOMAP consortium
doi : 10.1111/bjd.20587
Volume 185, Issue 5 p. 1066-1069
Histopathological differential diagnosis of frontal fibrosing alopecia and fibrosing alopecia in a pattern distribution
M.S. Teixeira,M.F.R. Gavazzoni Dias,E.A.G. Vilar,L. Pantaleão,R.F.R. Jourdan,C. Ekelem,M.C. Rochael
doi : 10.1111/bjd.20592
Volume 185, Issue 5 p. 1069-1070
Hidradenitis suppurativa among patients with HIV: investigating patient and disease characteristics and misdiagnosis
H. Bui,P.N. Skiba,A. Breskin,C. Sayed
doi : 10.1111/bjd.20591
Volume 185, Issue 5 p. 1070-1072
Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study
L.M. Prens,M.L. Porter,K.T. Savage,P. Salian,B. Horváth,A.B. Kimball
doi : 10.1111/bjd.20078
Volume 185, Issue 5 p. 1072-1074
Comparing the clinical differences in white and black women with frontal fibrosing alopecia
P. Adotama,V. Callender,A. Kolla,C. Young,P. Jones,K. Svigos,L. Yin,N. Ugonabo,D. Gutierrez,E. Peterson,K. Lo Sicco,J. Shapiro
doi : 10.1111/bjd.20605
Volume 185, Issue 5 p. 1074-1076
Essentiality and economy: a feasibility approach to evaluating suggested revisions to the World Health Organization Model List of Essential Medicines for skin disease
T.P. Joshi,V. Ren
doi : 10.1111/bjd.20565
Volume 185, Issue 5 p. 1077-1077
Patients who misuse alcohol have poorer responses to systemic treatments for psoriasis
doi : 10.1111/bjd.20717
Volume 185, Issue 5 p. e179-e179
This UK-based study was set up to understand what factors can influence the results of treatment among patients with psoriasis. Previous work has indicated that there is a link between bad psoriasis and alcohol consumption, and this study was designed to identify any connection between alcohol consumption and the response to treatment. The group studied were patients attending clinics in England. All had moderate to severe psoriasis and were treated with the topical or oral therapies in common use (conventional therapies) but some had received the newer biologic treatments. All patients completed a questionnaire that included questions on the patients’ self-estimate of misuse of alcohol as well as the severity of their psoriasis, which was recorded at various timepoints during treatment. Their information was recorded in a national database. Alcohol misuse and obesity were both associated with poorer responses to treatment with the conventional therapies. In addition, failure to stick to treatment schedules was also associated with poor results. At least 40% of those in this study reported psychological distress.
What do patients with psoriasis think about new approaches to reaching decisions about which biologic treatment to use?
doi : 10.1111/bjd.20718
Volume 185, Issue 5 p. e180-e180
Psoriasis is a common inflammatory skin condition that affects over a million people in the UK. Medicines called ‘biologics’ are a treatment option for patients but they do not work for everyone with psoriasis. Researchers are looking for new approaches to help doctors prescribe biologics. These new approaches use lots of information about the patient, including their genetics, to decide whether to use a biologic and, if so, which biologic is best for that individual; a process known as ‘stratified medicine’.
Brentuximab – effective for mycosis fungoides and Sézary syndrome
doi : 10.1111/bjd.20719
Volume 185, Issue 5 p. e181-e181
Mycosis fungoides (MF) and Sézary syndrome (SS) are rare forms of skin cancer (T-cell lymphoma) arising in the skin from white blood cells. They are variable in their behaviour and difficult to treat. Brentuximab vedotin (BV) is a drug that targets CD30, a protein found on the surface of activated T lymphocytes. CD30 is often expressed in patients with MF and SS.
Measuring the success of treatments for congenital melanocytic naevi (birthmarks)
doi : 10.1111/bjd.20720
Volume 185, Issue 5 p. e182-e182
Congenital melanocytic naevi (CMN) are birthmarks that can have a great impact on the lives of patients because of the unusual appearance of CMN and the risk of developing skin cancer (melanoma) or brain and spine problems. Larger CMN (more than 20 cm) are relatively rare and affect one in every 20,000 newborns. At the moment, different studies looking at CMN often measure different outcomes and this makes it difficult to compare studies.
Guidelines on how to manage basal cell carcinoma in adults
doi : 10.1111/bjd.20721
Volume 185, Issue 5 p. e183-e183
Basal cell carcinoma (BCC) is the most common type of skin cancer. It is usually caused by long-term ultraviolet light exposure from the sun and/or sunbeds. It is particularly common on the sun-exposed areas of the skin, especially in people with lightly pigmented skin types. It can also occur as part of rare inherited conditions (such as Gorlins syndrome). It does not generally spread internally to other parts of the body but if left untreated will slowly grow and can cause significant disfiguring damage.
How common is palmoplantar pustulosis in Sweden?
doi : 10.1111/bjd.20722
Volume 185, Issue 5 p. e184-e184
Palmoplantar (palmo meaning palm of the hand, plantar meaning sole of the foot) pustulosis (PPP) is a persistent (chronic) condition that causes blisters filled with fluid on the palms and the soles of the feet. The skin of the palms and soles can be very itchy and painful, particularly if there are deep cracks in the skin. The condition is persistent, but the symptoms can vary, becoming better and worse over time, often with no obvious cause.
What is known about the experiences of people with hidradenitis suppurativa?
doi : 10.1111/bjd.20723
Volume 185, Issue 5 p. e185-e185
Hidradenitis suppurativa (HS) is a long-term condition that causes abscesses on the skin especially in the groin, between buttocks, under breasts and in armpits.
Views about smartphone apps for skin cancer screening in the general population
doi : 10.1111/bjd.20724
Volume 185, Issue 5 p. e186-e186
Skin cancer is the most common type of cancer in the Netherlands. Smartphone applications (apps) have been developed that can help people in the general population to decide whether a visit to a doctor is necessary. In our study, from the Netherlands, we set out to explore the general public’s views about using apps to help identify skin cancers (skin cancer screening).
Is there a place for cell therapies in patients with severe psoriasis?
doi : 10.1111/bjd.20725
Volume 185, Issue 5 p. e187-e187
There have been major developments in the treatment of psoriasis, an immune-mediated skin disease, in recent years, most notably with ‘biologic’ therapies that target components of the immune system. However, these agents do not cure the disease and there are a few patients with severe psoriasis who fail to respond to any treatments currently available. Cell therapy has been used successfully in other immune-mediated conditions such as multiple sclerosis, Crohn disease and arthritis. It involves isolating and preparing cells from the patient (autologous) or a donor (allogeneic) and injecting them into the patient.
Air pollution causes skin darkening
doi : 10.1111/bjd.20726
Volume 185, Issue 5 p. e188-e188
Several animal species including pigeons, moths and sea snakes develop darker skin when exposed to urban or industrial pollution. This may be a protective mechanism: melanin (the pigment that gives human skin, hair and eyes their colour) can bind environmental toxins and dispose of them by normal skin-shedding. In this study, funded partly by companies marketing skincare products, researchers in Germany investigated this in human skin. The authors used both ‘ex vivo’ and ‘in vivo’ experiments. In ex vivo studies tissue is taken from a living organism, in this case people having operations, and then studied in a laboratory. In contrast, in in vivo studies the experiments are actually carried out in the living organism, in this case healthy volunteers.
????????????????????
doi : 10.1111/bjd.20727
Volume 185, Issue 5 p. e189-e189
????????, ?????????????????????????????, ??????????????, ??????????????????????????????????????????????????????????????, ?????????????????? (????) , ???????????????????????????, ??????????????????????????, ????????????????????????????????????????????????????????, ??????????????????????????? 40% ???????????
??????????????, ?????????????
doi : 10.1111/bjd.20728
Volume 185, Issue 5 p. e190-e190
???????????????, ??????????????????“????”?????????????, ????????????????????????????????????????????????????????, ?????????, ???????????, ?????, ????????????????????????“????”?
??????——??????? Sézary ?????
doi : 10.1111/bjd.20729
Volume 185, Issue 5 p. e191-e191
????? (MF) ? Sézary ??? (SS) ??????????? (T ?????) , ????????????????????????????????????? (BV) ????? CD30 ???, CD30 ?????????? T ?????????CD30 ??? MF ? SS ??????
???????? (??) ????????
doi : 10.1111/bjd.20730
Volume 185, Issue 5 p. e192-e192
???????? (CMN) ?????? CMN ???????????? (???) ?????????, ??????????????????? CMN (?? 20 cm) ????, ? 20,000 ?????? 1 ????, ??? CMN ????????????, ??????????
???????????
doi : 10.1111/bjd.20731
Volume 185, Issue 5 p. e193-e193
????? (BCC) ???????????????????/?????????????????????????????????, ????????????????????????????? (? Gorlins ???) ???????????????????????, ????????, ?????, ??????????????
???????????????
doi : 10.1111/bjd.20732
Volume 185, Issue 5 p. e194-e194
?? (?????) ??? (PPP) ?????? (??) ??, ?????????????????????????????????, ???????????????????, ?????????, ?????????????, ??????????
?????????????, ???????
doi : 10.1111/bjd.20733
Volume 185, Issue 5 p. e195-e195
?????? (HS) ???????, ???????, ????????????????????
???????????????????????????
doi : 10.1111/bjd.20734
Volume 185, Issue 5 p. e196-e196
????????????????????????? (app) ??????????????????????????, ????????????? app ??????? (?????) ????
???????????????????
doi : 10.1111/bjd.20735
Volume 185, Issue 5 p. e197-e197
??????????????, ????????????????????, ????????????????????“??”?????, ????????????, ??????????????????????????????????????????????, ???????????????????????? (??) ??? (??) ??????, ????, ????????????
?????????????
doi : 10.1111/bjd.20736
Volume 185, Issue 5 p. e198-e198
??????, ??????????, ????????????, ??????????????????: ??? (??????????????????) ?????????, ???????????????????????, ??????????????, ??????????????????????????“??”?“??”?????????, ???????? (?????, ??????) , ????????????????, ??????, ??????????, ????????????
